Related Experiment Video
Updated: Jun 29, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism
Ya-Hui Tsai1, Wan-Fen Kuang, Tsai-Yi Lu
1Graduate Institute of Microbiology, National Taiwan University College of Medicine, Taipei 100, Taiwan.
Background/Aims:
Patients infected with hepatitis C virus (HCV) genotype 2 or 3 usually respond better to interferon (IFN) treatment than those infected with genotype 1. In this study, we investigated whether the non-structural 5A protein (NS5A) of HCV genotypes 1 and 2 (1b-NS5A and 2a-NS5A, respectively) exerted differential counteractivities against IFN treatment.
Methods:
We compared the inhibitory effects of 1b-NS5As and 2a-NS5As on IFN activity. We also investigated the replication inhibition of HCV subgenomic replicons containing 1b-NS5A or 2a-NS5A in response to IFN treatment.
Results:
1b-NS5As exerted more profound inhibitory effects on IFN activity than 2a-NS5As. The replication of the 2a-NS5A-containing replicons was more sensitive to IFN treatment than that of the 1b-NS5A-containing replicons. Deletion of the interferon sensitivity-determining region/protein kinase R-binding domain (PKR-BD), the V3 domain, or the C-terminus region of NS5A significantly abrogated its anti-IFN activity. Domain swapping between 1b-NS5A and 2a-NS5A in the V3 domain and/or the C-terminus region resulted in a transfer of their anti-IFN activity.
Conclusions:
1b-NS5As exert higher magnitudes of IFN antagonism than do 2a-NS5As. The V3 and the C-terminus regions are responsible for the differential anti-IFN effects. This phenomenon may partly explain the genotype-linked differences in the response of HCV to IFN treatment.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Viral Hepatitis I: Introduction
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly

